Ascentage Pharma Group International (OTCPK:ASPHF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ascentage Pharma Group International PS Ratio Related Terms
Ascentage Pharma Group International PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International PS Ratio Chart
For the Biotechnology subindustry, Ascentage Pharma Group International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International PS Ratio vs Biotechnology Industry
Ascentage Pharma Group International PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ascentage Pharma Group International's Share Price of today is $4.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ascentage Pharma Group International (ASPHF) has a PS Ratio of 20.13 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ascentage Pharma Group International and its competitors. This is 59% below median its historical median of 49.07. Over the past decade, Ascentage Pharma Group International's PS Ratio has ranged from 9.84 to 1,000.00. According to the industry distribution chart, Ascentage Pharma Group International ranks #604 out of 929 companies in the Biotechnology industry, placing it in the top 65%.
Is Ascentage Pharma Group International's PS Ratio too high?
Ascentage Pharma Group International's current PS Ratio of 20.13 is 59% below median its 10-year median of 49.07. Over the past 10 years, this metric has ranged from a low of 9.84 to a high of 1,000.00. The Biotechnology industry median PS Ratio is 9.91. Ascentage Pharma Group International's value of 20.13 is 103.1% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #604 out of 929 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascentage Pharma Group International has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #604 out of 929 companies for PS Ratio. This places Ascentage Pharma Group International in the lower half of its industry. The industry median PS Ratio is 9.91. Ascentage Pharma Group International's value of 20.13 is 103.1% above this benchmark. Historically, Ascentage Pharma Group International's own PS Ratio has ranged from 9.84 to 1,000.00 over the past decade. While the company's 10-year median is 49.07 vs. the industry median of 9.91, Ascentage Pharma Group International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current PS Ratio of 20.13 is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current PS Ratio is 20.13, which is 59% below median its own 10-year median of 49.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.38, compared to a current price of $4.53 — trading 38.6% below its estimated fair value. The current PS Ratio is 20.13, which is 59% below median its 10-year median of 49.07 and 103.1% above the Biotechnology industry median of 9.91. Ascentage Pharma Group International's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current PS Ratio is 20.13 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 38.6% below its estimated GF Value™ of $7.38.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
PS Ratio: 20.13 (59% below median its 10-year median of 49.07)
GF Value™: $7.38 vs. price of $4.53 (38.6% below fair value)
Industry Position: 103.1% above the Biotechnology median (#604 of 929)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
66GF Score
Get the complete analysis for ASPHF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
